Table S1 Assessment of Methodological Quality of Cohort Studies

Table S1 Assessment of Methodological Quality of Cohort Studies

Study / Selection / Comparability / Outcome / Score
Representativeness of
exposed cohort / Selection of
non exposedcohort / Ascertainment
of exposure / Outcome of interest
not presentat start / Assessment of
outcome / Follow-up
length / Follow-up
adequacy
Campbell PJ[28] / * / * / * / * / * / * / - / - / 6
Cheung B[29] / * / * / * / * / * / - / - / - / 5
Heller PG[44] / * / * / * / * / - / * / * / - / 6
Stevenson WS[48] / * / * / * / * / - / - / - / - / 4
Finazzi G[30] / * / * / * / * / * / - / * / - / 6
Ohyashiki K[39] / * / * / * / * / * / * / - / - / 6
Pemmaraju N[45] / * / * / * / * / - / * / - / - / 5
Antonioli E[31] / * / * / * / * / * / * / * / - / 7
Larsen TS[32] / * / * / * / * / * / * / - / - / 6
Moreno MJ[33] / * / * / * / * / ** / - / * / - / 7
Wong RS[40] / * / * / * / * / * / - / * / - / 6
Arellano-Rodrigo E[34] / * / * / * / * / * / * / - / - / 7
Basquiera AL[46] / * / * / * / * / * / * / * / - / 7
Cho YU[41] / * / * / * / * / * / - / * / - / 6
Chim CS[42] / * / * / * / * / ** / * / * / * / 9
Patriarca A[35] / * / * / * / * / ** / - / * / - / 7
De Stefano V[36] / * / * / * / * / * / * / - / - / 6
Weston H[49] / * / * / * / * / * / * / * / - / 7
Pich A[37] / * / * / * / * / * / * / * / - / 7
Takata Y[43] / * / * / * / * / * / * / * / - / 7
Coucelo M[38] / * / * / * / * / * / * / * / - / 7
Ganata N[47] / * / * / * / * / * / * / * / * / 8

* Newcastle-Ottawa Quality Assessment Scale: study can have one star (*) for meeting each criterion, except that comparability (design or analysis) can have a maximum of two stars (**).

Table S2 Power analyses of studies

Study / Power of the Study（%）
Arterial Thrombosis / Venous Thrombosis / Microcirculatory Disturbancies
Campbell PJ[28] / 19 / 88.7 / NA
Cheung B[29] / 55.9 / 46 / NA
Heller PG[44] / 87 / 24.2 / 29.7
Finazzi G[30] / 49.7 / 20.7 / NA
Ohyashiki K[39] / 30.1 / 17.1 / NA
Pemmaraju N[45] / 7.3 / 24.8 / 50.3
Antonioli E[31] / 20 / 8.8 / 71.3
Larsen TS[32] / 93.2 / NA / 16.7
Moreno MJ[33] / 62.2 / 61.5 / NA
Wong RS[40] / 97.9 / 8.3 / NA
Arellano-Rodrigo E[34] / 7 / 7.9 / 6.3
Basquiera AL[46] / 9.2 / 13 / 18.9
Cho YU[41] / 11.3 / 13.1 / NA
Patriarca A[35] / 96.1 / 6.1 / NA
De Stefano V[36] / 97.9 / 83.5 / NA
Weston H[49] / 67.6 / 47.1 / NA
Pich A[37] / 7.3 / 6.6 / NA
Takata Y[43] / 37.4 / 5.5 / NA
Coucelo M[38] / 56.5 / 4.5 / NA
Ganata N[47] / 35.8 / 51.6 / 5
Meta-analysis / 100 / 99.8 / 72.5

*NA: not available

Figure S1Forest plots of the ORs for the risk of thrombosis between JAK2+ and JAK2- ET patients before diagnosis. (A) arterial thrombosis; (B) venous thrombosis.

Arterial Thrombosis before diagnosis png

Venous Thrombosis before diagnosis png

Figure S2Forest plots of the ORs for the risk of thrombosis between JAK2+ and JAK2- ET patients during follow-up. (A) arterial thrombosis; (B) venous thrombosis.

Arterial Thrombosis during follow up png

Venous Thrombosis during follow up png

Figure S3 the sensitive analysis for the risk of thrombosis between JAK2+ and JAK2- ET patients. (A) arterial thrombosis; (B) venous thrombosis.

Figure S4Funnel plots ofOR for thrombosis between JAK2+ and JAK2- ET patients. (A) arterial thrombosis; (B) venous thrombosis.